Study finds new biomarker for cognitive symptoms of schizophrenia, could serve as drug target

March 23, 2026
The researchers identified a previously unknown, freely circulating form of a brain protein called ‘Cacna2d1’ — levels of the protein were reduced among patients with schizophrenia, compared to the healthy participants, resulting in overactive or overexcited brain circuits.